News for Roche Holding AG (RO.SW)

AstraZeneca Plc may sell some of its medicines directly to patients in the US, joining several other drugmakers that have plans to bypass middlemen or are considering them. “We are absolutely considering this,” Chief Executive Officer Pascal Soriot said on a call with reporters after reporting better-than-expected sales and rising profit, spurred by growth in the US.

You should probably be saving more, but even if you can't do that, you can get more out of the money you are able to save.

Key Takeaways: Roche (RHHBY) plans to engage directly with U.S. consumers, potentially reducing drug prices by 50%. Analysts forecast a moderate upside f

The major U.S. index futures are currently pointing to a higher open on Wednesday, with stocks likely to move to the upside after ending the previous session mixed.

European stocks were sharply higher on Wednesday after three straight sessions of losses. Focus shifted to potential trade agreements after U.S. President Donald Trump announced trade deals with Japan & Philippines.

Key Takeaways: Roche's Genentech unit's asthma drug trial did not meet primary objectives. Analysts forecast a potential 12.84% stock upside with a targe

The report gave a little bit of everything to Fed policymakers who are divided as to whether tariffs will cause a one-time price shock or something more persistent.

Global economic updates including US inflation, China GDP, and European job data, with insights on tariffs, interest rates, and more.

Summary: Genentech, part of Roche (RHHBY), faces FDA rejection for expanded use of Columvi. Analysts set a one-year target for Roche with a projected ups

Roche (RHHBY) announces the retirement of key executives, Dr. Hans Clevers and Barbara Schädler, scheduled for 2025. Dr. Hans Clevers will retire from

Roche Holding AG (OTCQX:RHHBY) Virtual Hematology Investor Conference Call June 23, 2025 1:00 PM ETCompany ParticipantsBruno Eschli - Head of Investor...

Key Insights: Genentech's trial yields a 59% reduction in disease progression for lymphoma patients. Analysts forecast a potential 14.78% upside for Roch

Roche (RHHBY) halts Elevidys dosing for non-ambulatory Duchenne muscular dystrophy patients due to safety concerns. Two fatal acute liver failure cases

ETFs tracking the performance of weight-loss drugs have largely underperformed since launching in late 2023.

Perrigo has announced that Matt Winterman will become the company's new Executive Vice President, Product Supply, Operations Strategy and Transformation Officer

PR NewswireDUBLIN, June 4, 2025 Ron Janish, EVP Global Operations and Supply Chain, to RetireIndustry Veteran, Matt Winterman, Appointed EVP Product Supply

Alphabet gains on AI-driven cloud, while YouTube and Google One push subscriptions past 270M despite litigation and cloud competition concerns.

Roche's Itovebi receives positive backing from the European Medicines Agency for breast cancer treatment. Analyst forecasts suggest a potential 12.76% upsid

Roche (RHHBY) secures FDA approval for Susvimo, enhancing its treatment portfolio for diabetic retinopathy. Analyst consensus suggests a "Hold" rating w